These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 9062962)

  • 1. Aspirin delays thrombin generation in vitro through interaction with platelet phospholipids.
    Musiał J; Radwan J; Szczeklik A
    Thromb Res; 1997 Feb; 85(4):367-8. PubMed ID: 9062962
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of aspirin on platelet phospholipids.
    Valles J; Aznar J; Santos MT
    Thromb Haemost; 1976 Dec; 36(3):628-33. PubMed ID: 1037157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consideration of platelet effects in the selection of an anti-inflammatory agent.
    Small RE; Johnson SM
    Clin Pharm; 1987 Oct; 6(10):756-7. PubMed ID: 3505838
    [No Abstract]   [Full Text] [Related]  

  • 4. Non-steroidal anti-inflammatory drugs and platelet function.
    McQueen EG; Facoory B; Faed JM
    N Z Med J; 1986 May; 99(802):358-60. PubMed ID: 3464876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin.
    Undas A; Placzkiewicz-Jankowska E; Zieliński L; Tracz W
    Thromb Haemost; 2007 Jun; 97(6):1056-8. PubMed ID: 17549314
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of acetylsalicylic acid on aggregation of human platelets by Porphyromonas gingivalis.
    Whitaker EJ; Thomas IS; Falk JA; Obebe A; Hammond BF
    Gen Dent; 2007; 55(1):64-9; quiz 70, 79-80. PubMed ID: 17333971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
    Herault JP; Peyrou V; Savi P; Bernat A; Herbert JM
    Thromb Haemost; 1998 Feb; 79(2):383-8. PubMed ID: 9493595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin resistance: what, why and when?
    Shantsila E; Watson T; Lip GY
    Thromb Res; 2007; 119(5):551-4. PubMed ID: 17010411
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibitory effects of copper-aspirin complex on platelet aggregation.
    Shen ZQ; Chen ZH; Ma GY; Wang DC; Wu WL; Liu WP; Yang YK; Xiong HZ
    Zhongguo Yao Li Xue Bao; 1997 Jul; 18(4):358-62. PubMed ID: 10072923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
    Markuszewski L; Rosiak M; Golanski J; Rysz J; Spychalska M; Watala C
    Basic Clin Pharmacol Toxicol; 2006 May; 98(5):503-9. PubMed ID: 16635110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men.
    Tuleja E; Mejza F; Cmiel A; Szczeklik A
    Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1111-5. PubMed ID: 12730088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.
    Maree AO; Fitzgerald DJ
    Circulation; 2007 Apr; 115(16):2196-207. PubMed ID: 17452618
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibition of human platelet cathepsin A by non-steroidal anti-inflammatory drugs--in vitro study.
    Ostrowska H
    Pol J Pharmacol; 1996; 48(1):113-6. PubMed ID: 9112639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin acetylates nitric oxide synthase type 3 in platelets thereby increasing its activity.
    O'Kane P; Xie L; Liu Z; Queen L; Jackson G; Ji Y; Ferro A
    Cardiovasc Res; 2009 Jul; 83(1):123-30. PubMed ID: 19377066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombin formation in vitro in response to shear-induced activation of platelets.
    Fallon AM; Marzec UM; Hanson SR; Yoganathan AP
    Thromb Res; 2007; 121(3):397-406. PubMed ID: 17532367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates.
    Weyrich AS; Denis MM; Kuhlmann-Eyre JR; Spencer ED; Dixon DA; Marathe GK; McIntyre TM; Zimmerman GA; Prescott SM
    Circulation; 2005 Feb; 111(5):633-42. PubMed ID: 15668340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of non-selective, non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors on the PFA-100 closure time.
    Blaicher AM; Landsteiner HT; Zwerina J; Leitgeb U; Volf I; Hoerauf K
    Anaesthesia; 2004 Nov; 59(11):1100-3. PubMed ID: 15479319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets.
    Wu CC; Wang TW; Wang WY; Hsieh PW; Wu YC
    Eur J Pharmacol; 2005 Dec; 527(1-3):37-43. PubMed ID: 16313903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelets and phospholipids in tissue factor-initiated thrombin generation.
    Butenas S; Branda RF; van't Veer C; Cawthern KM; Mann KG
    Thromb Haemost; 2001 Aug; 86(2):660-7. PubMed ID: 11522019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coated-platelet levels are influenced by smoking, aspirin, and selective serotonin reuptake inhibitors.
    Prodan CI; Joseph PM; Vincent AS; Dale GL
    J Thromb Haemost; 2007 Oct; 5(10):2149-51. PubMed ID: 17883707
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.